No Data
Here's What Analysts Are Forecasting For 10x Genomics, Inc. (NASDAQ:TXG) After Its Second-Quarter Results
10x Genomics Second Quarter 2024 Earnings: Revenues Beat Expectations
Express News | 10x Genomics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results. The Company Announced Its CFO Will Resign
Buy Rating Affirmed for 10x Genomics Amidst Strategic Realignment and Promising Growth Prospects
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)
Maintaining Hold: Balancing 10x Genomics' Growth Prospects With Economic and Strategic Challenges
No Data
123456FEDCBA : why?
ForeverBean OP 123456FEDCBA : A friend of mine knows members of the management team and speaks highly of their capabilities--that's all![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
. I personally value the quality of management a lot when investing. So the cheaper it gets, the more I'm willing to buy.
ForeverBean OP 123456FEDCBA : But still, it's highly personal. So please don't take my words seriously.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
It's for long-term.
123456FEDCBA : Cool, thanks for sharing